Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Inactivated UPEC-FimON (Uro-Pathogenic E. coli) administered intravesically once weekly for 6 weeks. The dose will be escalated across sequential cohorts.”In the company’s words, NCT07881666 on ClinicalTrials.gov
- Tested for
- Urinary Bladder Neoplasms
- Main trialPhase 1
- “This is a Phase I, open-label, multicenter, dose-escalation study that aims to evaluate the safety and tolerability of intravesical inactivated Instillations of UPEC-FimON (Uro-Pathogenic E. coli) in participants with non-muscle invasive urothelial carcinoma (NMIUC) of the urinary bladder who failed previous Bacillus Calmette-Guérin (BCG) or intravesical chemotherapy. Up to 30 participants will be enrolled, with 3 participants per cohort, following a dose-escalation model, with the potential for dose expansion. Dose-escalation and dose modification decisions will be based on an assessment of…”In the company’s words, NCT07881666 on ClinicalTrials.gov
Other drugs for Urinary Bladder Neoplasms
- Cretostimogene GrenadenorepvecCG Oncology, Inc. · Phase 3
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2/3
- Disitamab vedotinPfizer · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- CetrelimabJohnson & Johnson (Janssen) · Phase 3
- TAR-200Johnson & Johnson (Janssen) · Phase 3
Coming up1
- 1 Sep 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 1 Sep 2027 | Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical Chemotherapy Failure |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026